# Can Adropin improve cardiac function in age-related heart failure?

Canonical source: https://retacompare.com/research/can-adropin-improve-cardiac-function-in-age-related-heart-failure

Peptide Longevity Q&A · 2025-11-18


    Research indicates that Adropin may reverse cardiac dysfunction associated with heart failure with preserved ejection fraction (HFpEF) in a mouse model, suggesting potential benefits for age-related cardiac health.

 What the research shows

The study investigated the effects of recombinant Adropin on cardiac dysfunction in a preclinical mouse model of HFpEF, a condition characterized by left ventricle diastolic dysfunction and myocardial structural remodeling. The researchers aimed to elucidate the molecular mechanisms driving cardiac dysfunction and whether Adropin could reverse these defects. Long-term treatment with Adropin was shown to reverse multiple markers of HFpEF-related cardiac dysfunction, including fibrosis, diastolic dysfunction, and cardiomyocyte hypertrophy. The study employed untargeted metabolomics to analyze metabolic changes and found that Adropin treatment reduced the activity of the hexosamine biosynthesis pathway, leading to a decrease in the O-GlcNAcylation of the cardiac fatty acid oxidation enzyme long chain acyl-CoA dehydrogenase (LCAD). This reduction in LCAD O-GlcNAcylation enhanced LCAD activity in vitro and decreased the accumulation of long-chain acylcarnitines in the hearts of HFpEF mice in vivo.

 Why it matters for longevity

The findings from this research highlight the potential of Adropin as a therapeutic agent in improving cardiac health, particularly in aging populations susceptible to HFpEF. As heart failure with preserved ejection fraction is prevalent among older adults, understanding how Adropin influences cardiac metabolism may lead to novel interventions that enhance healthspan and reduce age-related cardiac decline. By targeting metabolic pathways affected by aging, such as the hexosamine biosynthesis pathway, Adropin may offer a means to restore cardiac function and mitigate the impact of age-related changes in heart structure and function.

 Key findings at a glance

Adropin treatment reversed multiple markers of HFpEF-related cardiac dysfunction in a mouse model.

Long-term Adropin therapy reduced fibrosis, diastolic dysfunction, and cardiomyocyte hypertrophy.

Untargeted metabolomics revealed decreased activity in the hexosamine biosynthesis pathway following Adropin treatment.

Reduction in O-GlcNAcylation of LCAD was linked to improved cardiac fatty acid oxidation.

Adropin may restore cardiac metabolic function, presenting a potential therapeutic avenue for HFpEF.

 How Adropin works (background)

Adropin is an endogenous peptide hormone derived from the liver and brain, playing a crucial role in regulating energy metabolism and cardiovascular function. It has been implicated in various metabolic processes, including the modulation of insulin sensitivity and the regulation of lipid metabolism. The mechanism by which Adropin exerts its effects involves the modulation of specific metabolic pathways, including the hexosamine biosynthesis pathway, which is linked to cardiac dysfunction in HFpEF. By reducing the O-GlcNAcylation of enzymes such as LCAD, Adropin enhances fatty acid oxidation, thereby improving cardiac energy metabolism and function.

 Safety, caveats, and what we don't yet know

While the findings from this study are promising, it is important to note that the research was conducted in a preclinical mouse model. The applicability of these results to human populations requires further investigation. Additionally, the long-term safety and efficacy of Adropin treatment in humans have not yet been established. Future studies should aim to explore the effects of Adropin in diverse populations, including those with varying degrees of heart failure and metabolic dysfunction, to better understand its potential therapeutic role.

 Bottom line

Research suggests that Adropin may improve cardiac function in age-related heart failure by reversing key markers of cardiac dysfunction in a mouse model, indicating its potential as a therapeutic agent.

 Related questions

 How does Adropin affect metabolic health in older adults?

Research indicates that Adropin may play a role in regulating metabolic health, particularly in conditions associated with aging and metabolic dysfunction. Its effects on energy metabolism could have implications for age-related diseases.

 Can Adropin enhance recovery after cardiac events?

While specific studies on recovery post-cardiac events are limited, the potential of Adropin to improve cardiac function suggests it may aid in recovery processes following heart failure or other cardiac conditions.

 What is the role of Adropin in muscle health?

Adropin has been implicated in metabolic regulation, which may extend to muscle health. However, more research is needed to clarify its specific effects on muscle tissue, especially in the context of aging.

 Source: PubMed · bioRxiv · published 2025-11-18.

## Sources

- PubMed · bioRxiv: https://pubmed.ncbi.nlm.nih.gov/40654632/